Showing 5151-5160 of 6036 results for "".
- US Eye Network Expands into Southeastern US through Partnership with Carolina Eyecare Physicianshttps://modernod.com/news/us-eye-network-expands-into-southeastern-us-through-partnership-with-carolina-eyecare-physicians/2478319/Carolina Eyecare Physicians has joined the expanding US Eye network. With the addition of Carolina Eyecare Physicians, US Eye, a physician-led network of practices, will operate 24 clinics and 3 surgery centers. <
- Nicox Selects 0.1% NCX 470 Dose in Adaptive Stage of Mont Blanc Phase 3 Glaucoma Trialhttps://modernod.com/news/nicox-selects-0-1-ncx-470-dose-in-adaptive-stage-of-mont-blanc-phase-3-glaucoma-trial/2478316/Nicox SA announced the selection of the 0.1% dose of NCX 470 for phase 3 following the completion of the adaptive portion of the Mont Blanc phase 3 clinical trial. As is customary for adaptive design trials, in order to maintain the integrity of the trial, no data from the adaptive portion of the
- Lumenis Unveils Its First US Tour With Launch Of Mobile Outdoor Tradeshow Boothhttps://modernod.com/news/lumenis-unveils-its-first-us-tour-with-launch-of-mobile-outdoor-tradeshow-booth/2478311/Lumenis has announced its first mobile tour (LuMobile), September 28 through April 2021. The company will bring its flagship devices to practitioners in a safe environment aboard the new LuMobile outdoor tradeshow exhibit. The 20-city mo
- Apellis Announces Late-Breaking Presentation of Targeted C3 Therapy Pegcetacoplan in Patients with Geographic Atrophy (GA)https://modernod.com/news/apellis-announces-late-breaking-presentation-of-targeted-c3-therapy-pegcetacoplan-in-patients-with-geographic-atrophy-ga/2478309/Apellis Pharmaceuticals announced that a post hoc analysis of the phase 2 FILLY study investigating intravitreal pegcetacoplan (APL-2) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) has been accepted as a late-breaking oral presentation by EURETIN
- Moody’s: Hospital Financial Outlook Worse as COVID-19 Relief Funds Start to Dwindlehttps://modernod.com/news/moodys-hospital-financial-outlook-worse-as-covid-19-relief-funds-start-to-dwindle/2478308/For-profit hospitals are expected to see a financial decline over the next 12 to 18 months as federal relief funds that shored up revenue losses due to COVID-19 start to wane, a recent analysis from Moody’s said, according to a FierceHealthcare
- Rayner to Launch RayOne EMV Enhanced Monofocal IOLhttps://modernod.com/news/rayner-to-launch-rayone-emv-enhanced-monofocal-iol/2478303/Rayner has announced the upcoming European launch of RayOne EMV, a new fully preloaded non-diffractive IOL designed to enhance patient outcomes achieved with monovision. Developed in collaboration with Professor Graham Barrett, president of the Australasian Society of Cata
- Liminal BioSciences Provides Update on Progress on BLA for Ryplazim (Plasminogen)https://modernod.com/news/liminal-biosciences-provides-update-on-progress-on-bla-for-ryplazim-plasminogen/2478301/Liminal BioSciences announced that the FDA acknowledged receipt of the resubmission of the Biologic License Application (BLA) for Ryplazim (plasminogen) for the treatment of clinical signs and symptoms associated with congenital plasminogen deficiency (C-PLGD) in pediatrics and adults. The
- Neuro-Optometric Rehabilitation Association Announces Appointments of New Executive and Advisory Board Officershttps://modernod.com/news/neuro-optometric-rehabilitation-association-announces-appointments-of-new-executive-and-advisory-board-officers/2478297/The Neuro-Optometric Rehabilitation Association (NORA) announced the appointments of its new executive and advisory board members. DeAnn Fitzgerald, OD, assumes the position of President, succeeding Susan Daniel, OD, who now joins the NORA Advisory Board. Dr. Fitzgerald has been providing
- Oxford Says AstraZeneca Trial Illnesses May Not Be Linked to COVID-19 Vaccinehttps://modernod.com/news/oxford-says-astrazeneca-trial-illnesses-may-not-be-linked-to-covid-19-vaccine/2478290/Neurological symptoms developed by some volunteers in a trial testing AstraZeneca’s COVID-19 vaccine candidate AZD1222 either probably did not come about as a result of the vaccine, or there is not enough evidence to say one way or the other, according to the University of Oxford. The discl
- Santen Acquires Eyevance Pharmaceuticalhttps://modernod.com/news/santen-acquires-eyevance-pharmaceutical/2478289/In a move to enter the US pharmaceuticals market and expand its global presence, Santen announced it has acquired Eyevance Pharmaceutical for $225 million in cash. In the deal, Santen Holdings U.S. Inc., a wholly-owned subsidiary of Santen, will acquire all of the outstanding shares of Ey